Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422422 · ClinicalTrials.gov registry record · Phase 2
Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
A Phase 2 study of Epilepsy, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT00422422 is a Phase 2 study of Epilepsy that has completed, run by UCB Pharma. The registered enrollment target is 100 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00422422, a Phase 2 study of Epilepsy, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
Conditions Studied
Interventions
- DRUG Brivaracetam
Study Locations (20)
Other
- 202 - Brussels
- 203 - Brussels
- 201 - Leuven
- 502 - Hradec Králové
- 504 - Ostrava Porubo
- 501 - Prague
- 602 - Aguascalientes
- 611 - Chihuahua City
Florida
- 108 - Gulf Breeze
- 110 - Miami
- 103 - Wellington
New York
- 105 - Buffalo
- 104 - Rochester
Massachusetts
- 106 - Boston
Minnesota
- 101 - Saint Paul
Missouri
- 113 - Chesterfield
Ohio
- 107 - Cincinnati
Pennsylvania
- 114 - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422422
The ClinicalTrials.gov registry entry for NCT00422422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (89% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Brivaracetam is the first listed.
NCT00422422 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00422422 about?
NCT00422422 is a clinical study titled "Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.". Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.
What is the current status of trial NCT00422422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2011-07. Estimated completion is 2013-03.
What conditions does trial NCT00422422 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00422422?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT00422422?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422422 being conducted?
This trial has 20 study locations across Florida, Massachusetts, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.